ReviewBiochemistry and biophysics reports2026
Engineered exosomes for breast cancer immunotherapy: Emerging strategies and translational potential.
Review in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer remains one of the leading causes of cancer-related mortality in women worldwide, despite significant advances in early detection and conventional therapies. Immunotherapy has emerged as a promising strategy to harness the body's immune system to combat tumors. However, limitations such as immune escape mechanisms and inefficient drug delivery continue to challenge its effectiveness. In recent years, engineered exosomes, cell-derived nanoscale vesicles, have gained attention as innovative carriers for cancer immunotherapy due to their natural biocompatibility, low immunogenicity, and inherent targeting capabilities. This review highlights recent advancements in the design and functionalization of exosomes for breast cancer immunotherapy, including the loading of immune-stimulating molecules, genetic cargos, and surface modifications to enhance tumor specificity. We also discuss their advantages over conventional nanocarriers, immunological mechanisms, preclinical evidence, and challenges related to clinical translation. While significant progress has been made, further research is needed to overcome current barriers and fully exploit the potential of engineered exosomes as a next-generation platform in breast cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.